CONCORD DRUGS
Back to Balance Sheet
|
CONCORD DRUGS Last 5 Year Total Non-Current Liabilities History
[Consolidated]
| Mar2025 | Mar2024 | Mar2023 | Mar2022 | |
|---|---|---|---|---|
| Total Non-Current Liabilities | ₹4.85 Cr | ₹3.98 Cr | ₹4.91 Cr | ₹4.44 Cr |
What is the latest Total Non-Current Liabilities ratio of CONCORD DRUGS ?
| Year | Total Non-Current Liabilities |
|---|---|
| Mar2025 | ₹4.85 Cr |
| Mar2024 | ₹3.98 Cr |
| Mar2023 | ₹4.91 Cr |
| Mar2022 | ₹4.44 Cr |
How is Total Non-Current Liabilities of CONCORD DRUGS Trending?
| Years | Total Non-Current Liabilities | % Change | |
|---|---|---|---|
| Mar2025 | ₹4.85 Cr | 21.69 | |
| Mar2024 | ₹3.98 Cr | -18.89 | |
| Mar2023 | ₹4.91 Cr | 10.68 | |
| Mar2022 | ₹4.44 Cr | - | |
Compare Total Non-Current Liabilities of peers of CONCORD DRUGS
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| CONCORD DRUGS | ₹106.3 Cr | 13.4% | 16.9% | 61% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹456,114.0 Cr | NA | -3.9% | 17.3% | Stock Analytics | |
| DIVIS LABORATORIES | ₹239,321.0 Cr | 5% | 21.5% | 44.5% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹185,924.0 Cr | -2.1% | -0.2% | 34.3% | Stock Analytics | |
| CIPLA | ₹113,778.0 Cr | -2% | -2.5% | -8.1% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹99,025.9 Cr | 0.4% | 4.5% | -4.4% | Stock Analytics | |
CONCORD DRUGS Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| CONCORD DRUGS | 13.4% |
16.9% |
61% |
| SENSEX | 0.7% |
0.8% |
-5.1% |
You may also like the below Video Courses